SPARK UPS/MFS: Study Of BET Inhibition With ZEN003694 To Potentiate Anti-Tumor Responses With Radiotherapy To Kickstart Abscopal Effect In Metastatic Undifferentiated Pleomorphic Sarcoma (UPS) And Myxofibrosarcoma (MFS).
M.D. Anderson Cancer Center
Summary
This is a single-center, Phase 1/2 clinical trial evaluating the safety, tolerability, RP2D, and preliminary efficacy of ZEN003694 in combination with RT in patients with metastatic UPS and MFS who have completed first- or second- line doxorubicin-based chemotherapy without disease progression.
Description
Primary Objective: To evaluate the objective response rate (ORR) according to RECIST v1.1 at 12 weeks in patients treated with ZEN003694 and RT following first- or second- line doxorubicinbased chemotherapy compared to standard of care approach of surveillance. Secondary Objectives: * To estimate PFS following treatment with ZEN003694 and RT after first- or second- line doxorubicin-based chemotherapy. * To estimate the 12-month local control rate and time to local recurrence in primary and metastatic irradiated lesions local control rate. * To estimate OS following treatment with ZEN003694…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: Disease Characteristics * Histologically confirmed Stage IV metastatic UPS/MFS. Pathologic terms may include pleomorphic undifferentiated sarcoma, unclassified spindle cell sarcoma, spindle cell sarcoma not otherwise specified, pleomorphic spindle cell sarcoma, or pleomorphic fibroblastic sarcoma. • Patients must have completed at least 4 and no more than 6 cycles of doxorubicin-based first or second-line chemotherapy (single agent or in combination) at least 4 weeks out and within 12 weeks prior to enrollment and have not experienced progressive disease documented per…
Interventions
- DrugZEN003694
Given orally once daily
- DrugRadiation Therapy
The radiation therapy is to be delivered using a linear accelerator or proton gantry.
Location
- UT MD AndersonHouston, Texas